Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Summers Blasts NAD “Secret Rules” After J&J Ointment Claim Challenge

This article was originally published in The Tan Sheet

Executive Summary

Claims for Summers Labs’ Triple Paste diaper rash ointment spurred Desitin maker Johnson & Johnson to bring a challenge through the National Advertising Division. Summers disagreed with NAD’s conclusion on a physician survey it conducted and declined to discontinue a doctor-recommended claim.

You may also be interested in...



Bodyarmor Rejects NAD’s ‘Upgrade’ Claim Critique

Gatorade sports drinks Stokely-Van Camp challenged that Bodyarmor Nutrition was noncompliant with NAD’s April 2014 finding that its ads combined claims that are supported individually in such a way that they created unsupported comparative claims

Bodyarmor Rejects NAD’s ‘Upgrade’ Claim Critique

Gatorade sports drinks Stokely-Van Camp challenged that Bodyarmor Nutrition was noncompliant with NAD’s April 2014 finding that its ads combined claims that are supported individually in such a way that they created unsupported comparative claims

NAD Refers Star Herbs Blood Pressure Claims To FTC

The industry self-regulation group refers My Low Press supplement claims after Star Herbs fails to offer evidence to support its advertising. Referring uncooperative firms to FTC “was one of the things that we found attractive when we created our program with the NAD,” said CRN President and CEO Steve Mister.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel